Poblete M T, Nualart F, del Pozo M, Perez J A, Figueroa C D
Department of Pathology, Hospital John F. Kennedy, Valdivia, Chile.
Am J Surg Pathol. 1996 Aug;20(8):956-63. doi: 10.1097/00000478-199608000-00004.
Alpha 1-antitrypsin is a plasma serine protease inhibitor originally used as a marker for tumors of histiocytic origin. Our casual finding of immunoreactive alpha 1-antitrypsin in one case of thyroid papillary carcinoma led us to investigate its presence in 10 thyroid papillary carcinomas by applying immunocytochemical and immunochemical techniques to tissue sections and Western blots of tissue homogenates prepared from neoplastic tissue and from uninvolved normal areas in the vicinity of each tumor. The immunocytochemical study was performed in both thyroid tissue and metastatic regional lymph nodes. This analysis revealed immunoreactivity for alpha 1-antitrypsin in nine of the 10 cases studied. Immunoreactivity was intense in some of the cells forming the papillar and follicular structures. These cells were intermingled with completely unstained tumoral cells. In contrast to neoplastic tissue, the normal thyroid tissue present in the vicinity of each tumor showed no staining for alpha 1-antitrypsin. The electrophoretic analysis performed on homogenates prepared from both tumoral and normal thyroid tissue revealed a drastic reduction in the band corresponding to thyroglobulin in the tumoral tissue compared with normal thyroid extracts, where it represented the major protein. Western blotting and immunoprinting with a polyclonal alpha 1-antitrypsin antibody confirmed the results obtained with immunocytochemistry about the presence of this protease inhibitor in neoplastic thyroid tissue. Immunoprinting with the anti-alpha 1-antitrypsin antibody revealed an intense immunoreactive band of 53 kDa in the extracts prepared from tumoral tissue. This band had exactly the same apparent molecular mass previously described by others for alpha 1-antitrypsin purified from plasma and was identical to the molecular mass of the purified commercial standard employed.
α1 - 抗胰蛋白酶是一种血浆丝氨酸蛋白酶抑制剂，最初用作组织细胞源性肿瘤的标志物。我们在一例甲状腺乳头状癌中偶然发现了免疫反应性α1 - 抗胰蛋白酶，这促使我们通过对肿瘤组织及每个肿瘤附近未受累正常区域制备的组织匀浆进行免疫细胞化学和免疫化学技术检测，来研究其在10例甲状腺乳头状癌中的存在情况。免疫细胞化学研究在甲状腺组织和转移性区域淋巴结中均进行。该分析显示，在研究的10例病例中有9例对α1 - 抗胰蛋白酶呈免疫反应性。在形成乳头和滤泡结构的一些细胞中免疫反应性很强。这些细胞与完全未染色的肿瘤细胞混合在一起。与肿瘤组织形成对比的是，每个肿瘤附近的正常甲状腺组织对α1 - 抗胰蛋白酶无染色。对肿瘤和正常甲状腺组织制备的匀浆进行的电泳分析显示，与正常甲状腺提取物相比，肿瘤组织中对应甲状腺球蛋白的条带急剧减少，在正常甲状腺提取物中甲状腺球蛋白是主要蛋白质。用多克隆α1 - 抗胰蛋白酶抗体进行的蛋白质印迹和免疫印记证实了免疫细胞化学关于这种蛋白酶抑制剂在肿瘤性甲状腺组织中存在的结果。用抗α1 - 抗胰蛋白酶抗体进行免疫印记显示，肿瘤组织提取物中有一条53 kDa的强免疫反应性条带。这条带的表观分子量与其他人先前描述的从血浆中纯化的α1 - 抗胰蛋白酶完全相同，并且与所使用的纯化商业标准品的分子量一致。
